Key Drivers
- Gross margin strength
- Operating loss burden
- Rising leverage
AIAI Summary
URGN has shifted from a speculative biotech to a real commercial growth story as ZUSDURI and JELMYTO drive revenue and UGN-103 adds upside, but the investment now depends on management proving it can outgrow persistent losses, rising debt, and the looming JELMYTO exclusivity overhang before the rich valuation gets ahead of fundamentals.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross margin strength
- •Operating loss burden
- •Rising leverage
URGN has strong product economics with ~90%+ gross margins, but heavy operating losses, persistent cash burn, rising debt, and negative equity make the investment case risky despite adequate near-term liquidity.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Breakout held
- •Near-term stretched
URGN has trended sharply higher over the last month, breaking through prior resistance and holding higher lows, but it is now extended near the top of its range and vulnerable to a short-term pause or pullback.
Sharp run-up from $26.60 to $38.02 over the last month leaves the stock short-term overbought
Sentiment & News
Key News Insights:
- •Executive selling
- •Investor engagement
- •Equity grants
UroGen's 2026 updates reflect routine corporate activity and investor engagement, but repeated share sales by CMO Mark Schoenberg are the main notable signal.
The stock may see limited immediate operational impact, but repeated insider sales could weigh on investor sentiment
Similar Companies in Healthcare
Other companies in the same sector with AI ratings